Phase I/IIa

Quotient Bioresearch has a strong heritage in First-in-Human (FIH) studies. This is complemented by our specialist early development services, including unique capabilities to speed the development process from FIH through to proof of concept.

We conduct the full range of human pharmacology studies on all types of drug candidate. Our objectives are to assess tolerability, define/describe PK and PD and explore drug metabolism and drug interactions. These studies can be augmented with our range of clinical services to help identify “developability” issues prior to embarking on Phase I and guide your decision making on further clinical development strategies. For more information see drug product optimisation and ¹⁴C enabled drug development services.

We can accommodate all Phase I study designs and provide references from customers in global pharmaceutical companies through to small “virtual” biotech companies worldwide.